4 results
To determine the toxicity of adding chloroquine in escalating doses in patients with small cell lung cancer to standard therapy.
To evaluate the inter- and intra-subject variability in pharmacokinetics (PK) and pharmacodynamics (PD) of study drug following a two-period repeated single dose of 2 mg delivered by subcutaneous (SC) injection in healthy volunteers.
The primary objective is to examine whether a combined treatment with rivastigmine (cholinesterase inhibitor) and citalopram (selective serotonin re-uptake inhibitor) will improve memory as compared to the treatment with either rivastigmine or…
To determine the toxicity of adding chloroquine in escalating doses in patients with small cell lung cancer to standard therapy.